Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.

Citation data:

Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN: 1078-0432, Vol: 21, Issue: 6, Page: 1267-72

Publication Year:
2015
Usage 8
Abstract Views 7
Link-outs 1
Captures 44
Readers 44
Social Media 8
Tweets 4
Shares, Likes & Comments 4
Citations 13
Citation Indexes 13
PMID:
25770294
DOI:
10.1158/1078-0432.ccr-14-2877
PMCID:
PMC4360883
Author(s):
Bachanova, Veronika; Frankel, Arthur E; Cao, Qing; Lewis, Dixie; Grzywacz, Bartosz; Verneris, Michael R; Ustun, Celalettin; Lazaryan, Aleksandr; McClune, Brian; Warlick, Erica D; Kantarjian, Hagop; Weisdorf, Daniel J; Miller, Jeffrey S; Vallera, Daniel A Show More Hide
Publisher(s):
American Association for Cancer Research (AACR)
Tags:
Medicine; Biochemistry, Genetics and Molecular Biology
Most Recent Tweet View All Tweets
article description
The novel bispecific ligand-directed toxin (BLT) DT2219 consists of a recombinant fusion between the catalytic and translocation enhancing domain of diphtheria toxin (DT) and bispecific single-chain variable fragments (scFV) of antibodies targeting human CD19 and CD22. We conducted a phase I dose-escalation study to assess the safety, maximum tolerated dose, and preliminary efficacy of DT2219 in patients with relapsed/refractory B-cell lymphoma or leukemia.